Composition and method for treating and relieving myopia

Patent metadata

Field	Value
Publication number	US-2016120833-A1
Application number	US-201514926519-A
Country	US
Kind code	A1
Filing date	Oct 29, 2015
Priority date	Oct 31, 2014
Publication date	May 5, 2016
Grant date	—

Abstract

The present invention provides a pharmaceutical composition for treating and/or relieving myopia, the pharmaceutical composition comprises a therapeutically effective amount of an anti-inflammatory agent and a pharmaceutically acceptable carrier; the pharmaceutical composition of the present invention is safe, and can treat and/or relieve myopia by the anti-inflammatory agent. The pharmaceutically acceptable carrier can effectively encapsulate the anti-inflammatory agent at a specific ratio, and the stability and solubility of the pharmaceutical composition can be enhanced.

First claim

What is claimed is:

1 . A pharmaceutical composition for use in treating and/or relieving myopia comprising: a therapeutically effective amount of an anti-inflammatory agent and a pharmaceutically acceptable carrier, wherein the anti-inflammatory agent comprises resveratrol, diacerein or diclofenac.

2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises potyoxyethylene castor oil ether (Cremophor EL), alkyldimethylbenzylammonium (BKC), lecithin, cholesterol, Dulbecco's phosphate buffered saline (DPBS), cyclodextrin, tween 80, castor oil, artificial tears, and any combination thereof.

3 . The pharmaceutical composition of claim 1 , wherein the anti-inflammatory agent is resveratrol, the concentration of resveratrol is between 0.1 M and 0.2 M, and the pharmaceutically acceptable excipient comprises cyclodextrin and artificial tears.

4 . The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition comprises 0.1141 g resveratrol, 1.46 g cyclodextrin and 1 ml artificial tears.

5 . The pharmaceutical composition of claim 1 , wherein the anti-inflammatory agent is diacerein, the concentration of diacerein is between 0.01 M and 0.02 M, and the pharmaceutically acceptable excipient comprises tween 80, castor oil and artificial tears.

6 . The pharmaceutical composition of claim 5 , wherein the volume ratio of tween 80 to castor oil is 0.01 to 0.02:0.003 with a total volume of artificial tears.

7 . The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition comprises 0.004 g diacerein, 1 ml artificial tears, 10 μl tween 80 and 3 μl castor oil.

8 . The pharmaceutical composition of claim 1 , wherein the anti-inflammatory agent is diclofenac, the concentration of diclofenac is between 0.01 M and 0.02 M, and the pharmaceutically acceptable excipient comprises artificial tears.

9 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition comprises 0.004 g diclofenac and 1 ml artificial tears.

10 . A method for preparing said pharmaceutical composition as claimed in claim 1 comprising:
preparing the anti-inflammatory agent;
preparing the pharmaceutically acceptable carrier; and
adding the therapeutically effective amount of the anti-inflammatory agent gradually into the pharmaceutically acceptable carrier under an oscillating condition to obtain the pharmaceutical composition.

11 . The method of claim 10 , wherein the anti-inflammatory agent is resveratrol, the pharmaceutically acceptable excipient comprises cyclodextrin and artificial tears; the resveratrol is enveloped by cyclodextrin, a molar ratio of resveratrol to cyclodextrin is 1:2 to form a cladding, and the cladding is added to artificial tears at a weight ratio of 0.01 to 0.03:1 progressively and gradely to obtain the pharmaceutical composition.

12 . The method of claim 10 , wherein the anti-inflammatory agent is diacerein, the pharmaceutically acceptable excipient comprises tween 80, castor oil and artificial tears; the volume ratio of tween 80 to castor oil is 0.01 to 0.02:0.003 with a total volume of artificial tears to form a mixture, and then diacerein is added to the mixture progressively and gradely to obtain the pharmaceutical composition.

13 . The method of claim 10 , wherein the anti-inflammatory agent is diclofenac, the pharmaceutically acceptable excipient comprises artificial tears; diacerein is added to the mixture progressively and gradely with the weight ratio of diclofenac to artificial tears being 0.03 to 0.06:0.001 to obtain the pharmaceutical composition.

14 . A method for treating and/or relieving myopia comprising a step of administering to a subject in a topical in need thereof the therapeutically effective amount of the pharmaceutical composition as claimed in claim 1 .

15 . The method of claim 14 , wherein the subject is animal or human.

16 . The method of claim 14 , wherein the administration comprises oral administration, topical injection or external use.

17 . The method of claim 14 , wherein the topical is eyeball.

18 . The method of claim 16 , wherein the therapeutically effective amount of the pharmaceutical composition for treating and/or relieving myopia in external dosage form is between 0.5% and 1%.

19 . The method of claim 16 , wherein the therapeutically effective amount of the pharmaceutical composition for treating and/or relieving myopia in oral administration form is between 10 mg/day and 50 mg/day.

20 . The method of claim 16 , the external dosage form of the pharmaceutical composition is ointments, drops or gels.

Assignees

• Sundragon Biomedical Electronics Co Ltd
• Univ China Medical

Inventors

• Wan Lei
• Lin Hui-Ju

Classifications

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K31/235

  having an aromatic ring attached to a carboxyl group · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title